DeutschNewstral
Article
Dallas News on 2023-03-01 19:45
Reata stock soars on FDA approval for ultra-rare disease drug after 15 years
Related news
- Plano’s Reata Pharmaceuticals halts chronic kidney disease drug developmentDallas News
- MCelgene's rare disease drug gets FDA approvalmarketwatch.com
- BReata Soars on Approval for Rare Disorder Drug. Its Pipeline Impresses Analysts.1 min readbarrons.com
- BNeos Therapeutics stock soars on FDA approval for ADHD drugbizbeatblog.dallasnews.com
FDA approves ultra-rare disease drug from Waltham's Sobibizjournals.com
FDA broadens approval for fish-oil derived heart disease drugnewatlas.com- MSarepta’s surprise FDA approval for rare disease drug excites investorsmarketwatch.com
Leadiant gets FDA approval for treatment for rare diseasethedailyrecord.com- Albireo gets FDA, European approval for pediatric liver disease drugbizjournals.com
- Shire wins FDA approval for potential blockbuster rare disease drugbizjournals.com
- First therapy for childhood aging disease wins FDA approvalbizjournals.com
- Biogen scores FDA approval for generic eye disease biologicbizjournals.com
- MVericel's stock soars in premarket-leading volume after FDA approval of cartilage repair productmarketwatch.com
FDA grants approval for second COVID-19 vaccine as pandemic death toll soarsthenewstribune.com- MKaryopharm's stock soars to lead Nasdaq gainers before halt; XPOVIO gets FDA approvalmarketwatch.com
- MInsys's stock soars after cannabis-based oral drug gets FDA approvalmarketwatch.com
- TFDA-Approval of Palforzia for Peanut Allergytherip.com
Diabetes drug gets FDA sale approvalArkansas Online